Ongoing Clinical Trials
AT1001 currently is being studied in people who have Fabry disease in a Phase 3 U.S. registration trial. The study began enrolling subjects in the Fall of 2009 and is being conducted in medical centers globally. Enrollment criteria, site locations, and specifics for this trial may be found by visiting www.clinicaltrials.gov and searching the keyword “Amicus” or by clicking here.
AT2220 is currently in a Phase 1 study. The primary objective of this study is to evaluate the pharmacokinetics of AT2220 in muscle tissue in healthy adult subjects.
Enrollment criteria, site locations, and specifics for this trial may be found by visiting www.clinicaltrials.gov and searching the keyword “Amicus” or by clicking here.